Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with a DNA hypomethylating agent or low dose cytarabine, results…
Related Articles
Management of Heart Failure With Reduced Ejection Fraction
Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical condition characterized by dyspnea and functional impairmen…
Management of Heart Failure With Reduced Ejection Fraction
Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical condition characterized by dyspnea and functional impairmen…
The Impact of CMV Reactivation on Mortality After Chimeric Antigen Receptor T-Cell Therapy
Eleftheria Kampouri, Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal, Terry L Stevens-Ayers, Damian J Green, Jordan Gauthier, Mazyar Shadma
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy
Key Points. Based on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (G
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study
Key Points. Bridging radiotherapy prior to CAR-T was well-tolerated with minimal toxicity in this large multicenter studyComprehensive bridging radiotherap
Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL
Key Points. A phase 2 academic clinical trial of CD19 CAR T cells demonstrates durable remissions with a 1-year LFS in low disease burden groups…
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy
Key Points. Based on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (G
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma
Key Points. Maintenance romidepsin post-AHCT in an unselected population of patients with PTCL did not meet a primary efficacy endpoint.Maintenance romidep
Immunological Consequences of CAR T-Cell Therapy – Analysis of Infectious Complications and Immune Reconstitution
Key Points. CAR T-cells induce a cellular and humoral immunodeficiency resulting in an initial susceptibility for bacterial and later viral infectionsSever
Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Initial Response to Intensive Chemotherapy Induction
Key Points. No clearance of mid-cycle-marrow blasts in patients with IDH2R172-mutated AML after intensive induction, despite later achieving CRKinetics of